Virtus Biotech Clinical Trials ETF
17 hedge funds and large institutions have $7.9M invested in Virtus Biotech Clinical Trials ETF in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 3 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
28% more capital invested
Capital invested by funds: $6.15M → $7.9M (+$1.75M)
6% more funds holding
Funds holding: 16 → 17 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$1.37M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$576K |
| 3 |
LPL Financial
San Diego,
California
|
+$408K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$275K |
| 5 |
LSA
Liberty Street Advisors
New York
|
+$203K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.08M |
| 2 |
Jane Street
New York
|
-$471K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$14.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7.34K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$2.89K |
BBC Hedge Fund Activity: Q4 2015 in Review
17 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q4 2015, worth a combined $7.9M — up 28% from $6.15M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BBC positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Virtu KCG Holdings, adding an estimated $1.37M. The largest seller was Credit Suisse, exiting entirely with an estimated $1.08M sold.
- 17 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q4 2015, up from 16 in Q3 2015.
- Funds reported $7.9M of Virtus Biotech Clinical Trials ETF stock for Q4 2015, up 28% quarter-over-quarter.
- 4 funds opened new Virtus Biotech Clinical Trials ETF positions in Q4 2015 and 3 closed out, a net change of +1 holder.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q4 2015 was Virtu KCG Holdings, an estimated $1.37M added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q4 2015 was Credit Suisse, an estimated $1.08M sold.
Based on aggregated 13F filings for Q4 2015.